The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Nanoparticles containing insoluble drug for cancer therapy
Open accessAbstract
Nanoparticle drug formulations have been extensively researched and developed in the field of drug delivery as a means to efficiently deliver insoluble drugs to tumor cells. By mechanisms of the enhanced permeability and retention effect, nanoparticle drug formulations are capable of greatly enhancing the safety, pharmacokinetic profiles and bioavailability of the administered treatment. Here, the progress of various nanoparticle formulations in both research and clinical applications is detailed with a focus on the development of drug/gene delivery systems. Specifically, the unique advantages and disadvanges of polymeric nanoparticles, liposomes, solid lipid nanoparticles, nanocrystals and lipid-coated nanoparticles for targeted drug delivery will be investigated in detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“Liposomes that are 100–200 nm in diameter readily accumulate in the tumor interstitium because of the enhanced permeability and retention (EPR) effect (Fang et al., 2011; Maeda et al., 2000).”
BackgroundDrug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 1×
“Among the polymers, PLA and PLGA, have been the most extensively investigated for use in drug delivery due to their biocompatibility and controlled release through the hydrolysis of the ester bonds (Li et al., 2011; Makadia and Siegel, 2011).”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 3×
“Liposomal formulation Doxil®/ Caelyx® PEGylated liposomal doxorubicin Janssen Pharmaceuticals Treats Kaposi’s sarcoma; metastatic breast &ovarian cancers, FDA approved (Barenholz, 2012)”
BackgroundMethodCancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558 · cited 2×
“Introduction Over the past two decades, nanomedicine has emerged as a catalyst for the advancement of new pharmaceutical formulations (Ferrari, 2005; Panyam and Labhasetwar, 2003; Shi et al., 2010).”
BackgroundKalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“Recently, many studies have shown that cancer-associated fibroblasts have significantly contributed to angiogenesis in tumor, tumor’s growth, invasion and metastasis (Kalluri and Zeisberg, 2006).”
BackgroundBiodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222 · cited 1×
“Stroma also increases IFP, leading to low penetration of drug in the tumor (Heldin et al., 2004).”
BackgroundJain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151 · cited 3×
“…methotrexate-, and camptothecin-conjugates which are each cleaved by a unique combination utilizing two to three of the following: matrix metalloproteases 2 and 9, cathepsin B, urokinase, prostatespecific antigen (PSA), plasmin or proteases (Kratz, 2008; Warnecke et al., 2007).”
BackgroundSaito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407 · cited 1×
“Thereafter, many efforts have been made to tailor the conjugate using pH-sensitive or enzyme degradable linkers (Duncan, 2006; Saito et al., 2003).”
BackgroundFormulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078 · cited 1×
“However, the majority of polymeric nanoparticles are formulated through a self-assembly process using hydrophilic and hydrophobic block copolymers (Adams et al., 2003; Rösler et al., 2001).”
BackgroundPLGA Nanoparticles in Drug Delivery: The State of the Art;
Bala, I., Hariharan, S., & Kumar, M. R. (2004) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v21.i5.20 · Cited by 739
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1×
“Another promising polymeric nanoparticle formulation is nab-paclitaxel (Abraxane) (Green et al., 2006; Miele et al., 2009).”
BackgroundLee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541 · cited 3×
“Similarly, to increase the solubility of paclitaxel, Mirkin et al. attached paclitaxel-oligonucleotide-thiol conjugated on to the surface of gold nanoparticles (Lee et al., 2008a).”
BackgroundDanson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382 · cited 2×
“, 2011) is particularly active in treating multidrug resistant (MDR) and metastatic cancers (Danson et al., 2004; Dumortier et al., 2006); the poloxamer disrupts mitochondrial functionality in chemo-resistant cells by depleting ATP and releasing reactive oxygen species (ROS) and cytochrome C.”
BackgroundLiu, J., Xiao, Y., & Allen, C. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10533 · Cited by 358 · cited 2×
“To maximize the loading of drugs in polymeric nanoparticles, the drug and carrier must be perfectly matched in miscibility (Liu et al., 2004; Xiong et al., 2011).”
BackgroundValle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603855 · Cited by 290
In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants
Ramchandani, M., & Robinson, D. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00113-2 · Cited by 195
In vivo delivery of RNAi with lipid-based nanoparticles
Huang, L., & Liu, Y. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124709 · Cited by 174
Self-citationEsmaeili, F., Ghahremani, M. H., Esmaeili, B., Khoshayand, M. R., Atyabi, F., & Dinarvand, R. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.07.038 · Cited by 159
Amann, L. C., Gandal, M. J., Lin, R., Liang, Y., & Siegel, S. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0152-4 · Cited by 99 · cited 1×
“By adjusting the composition of PLGA through alteration of the ratio between lactide and glycolide, the release rate of drugs can be adjusted from a scale of days to months (Amann et al., 2010; Faisant et al., 2002; Ramchandani and Robinson, 1998).”
Background
Cited by
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 914
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
“Compared with the direct administration of free drugs, encapsulation of drugs in nanocarriers provides distinct advantages, including better drug solubility[55-57], improved pharmacokinetic[58, 59] and pharmacodynamic properties[60, 61], prolonged circulation time[62, 63], minimized side effects[64], and sustained dru…”
BackgroundRecent applications of PLGA based nanostructures in drug delivery
Mir, M., Ahmed, N., & Rehman, A. U. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.07.038 · Cited by 621
Strategies to improve micelle stability for drug delivery
Lu, Y., Zhang, E., Yang, J., & Cao, Z. (2018) · Nano Research · doi:10.1007/s12274-018-2152-3 · Cited by 530
Metadata
- Authors
- Guo, S., & Huang, L.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 32
- Issue
- 4
- Pages
- 778-788
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W1985781888
- Cited by
- 159
- References
- 24
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.